Senores Pharmaceuticals gains on inking agreement to acquire ANDA for Tramadol Tablets
Senores Pharmaceuticals is currently trading at Rs 482.25, up by 0.55 points or 0.11% from its previous closing of Rs 481.70 on the BSE.
The scrip opened at Rs 476.15 and has touched a high and low of Rs 484.00 and Rs 474.00 respectively. So far 2170 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52-week high of Rs 664.00 on 19-Mar-2025 and a 52-week low of Rs 440.00 on 13-Jan-2025.
Last one week high and low of the scrip stood at Rs 537.00 and Rs 474.00 respectively. The current market cap of the company is Rs 2220.93 crore.
The promoters holding in the company stood at 45.77%, while Institutions and Non-Institutions held 13.82% and 40.40% respectively.
Senores Pharmaceuticals, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Tramadol Tablets from APDM Pharmaceuticals (APDM).
Tramadol is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by company. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
